Development of a Novel Human CD147 Knock-in NSG Mouse Model to Test SARS-CoV-2 Viral Infection

Saiaditya Badeti
Rutgers New Jersey Medical School

Qingkui Jiang
Rutgers New Jersey Medical School

Alireza Naghizadeh
Rutgers New Jersey Medical School

Hsiang-chi Tseng
Rutgers New Jersey Medical School

Yuri Bushkin
Rutgers New Jersey Medical School

Salvatore A.E. Marras
Rutgers New Jersey Medical School

Annuurun Nisa
Rutgers New Jersey Medical School

Sanjay Tyagi
Rutgers New Jersey Medical School

Fei Chen
Rutgers New Jersey Medical School

Peter Romanienko
Rutgers Cancer Institute of New Jersey

Ghassan Yehia
Rutgers Cancer Institute of New Jersey

Deborah Evans
Rutgers New Jersey Medical School

Moises Lopez-Gonzalez
Rutgers New Jersey Medical School

David Alland
Rutgers New Jersey Medical School

Riccardo Russo
Rutgers New Jersey Medical School

William Gause
Research Article

Keywords: CD147, Basigin, BSG, hCD147KI, NSG, SARS-CoV-2, COVID-19, Viral Entry, accessory receptor, immune responses

Posted Date: April 20th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1431484/v1

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** An animal model that can mimic the SARS-CoV-2 infection in humans is critical to understanding the rapidly evolving SARS-CoV-2 virus and for development of prophylactic and therapeutic strategies to combat emerging mutants. Studies show that the spike proteins of SARS-CoV and SARS-CoV-2 bind to human angiotensin-converting enzyme 2 (hACE2, a well-recognized, functional receptor for SARS-CoV and SARS-CoV-2) to mediate viral entry. Several hACE2 transgenic (hACE2Tg) mouse models are being widely used, which are clearly invaluable. However, the hACE2Tg mouse model cannot fully explain: 1) low expression of ACE2 observed in human lung and heart, but lung or heart failure occurs frequently in severe COVID-19 patients; 2) low expression of ACE2 on immune cells, but lymphocytopenia occurs frequently in COVID-19 patients; and 3) hACE2Tg mice do not mimic the natural course of SARS-CoV-2 infection in humans. Moreover, one of most outstanding features of coronavirus infection is the diversity of receptor usage, which includes the newly proposed human CD147 (hCD147) as a possible co-receptor for SARS-CoV-2 entry. It is still debatable whether CD147 can serve as a functional receptor for SARS-CoV-2 infection or entry.

**Results:** Here we successfully generated a hCD147 knock-in mouse model (hCD147KI) in the NOD-scid IL2Rgamma null (NSG) background. In this hCD147KI-NSG mouse model, the hCD147 genetic sequence was placed downstream of the endogenous mouse promoter for mouse CD147 (mCD147), which creates an *in vivo* model that may better recapitulate physiological expression of hCD147 proteins at the molecular level compared to the existing and well-studied K18-hACE2-B6 (JAX) model. In addition, the hCD147KI-NSG mouse model allows further study of SARS-CoV-2 in the immunodeficiency condition which may assist our understanding of this virus in the context of high-risk populations in immunosuppressed states. Our data show 1) the human CD147 protein is expressed in various organs (including bronchiolar epithelial cells) in hCD147KI-NSG mice by immunohistochemical staining and flow cytometry; 2) hCD147KI-NSG mice are marginally sensitive to SARS-CoV-2 infection compared to WT-NSG littermates characterized by increased viral copies by qRT-PCR and moderate body weight decline compared to baseline; 3) a significant increase in leukocytes in the lungs of hCD147KI-NSG mice, compared to infected WT-NSG mice.

**Conclusions:** hCD147KI-NSG mice are more sensitive to COVID-19 infection compared to WT-NSG mice. The hCD147KI-NSG mouse model can serve as an additional animal model for further interrogation whether CD147 serve as an independent functional receptor or accessory receptor for SARS-CoV-2 entry and immune responses.

**Background**

SARS-CoV-2 is the novel coronavirus that causes Coronavirus-Disease of 2019 (COVID-19) and has become a global pandemic and devastated millions. While there are many similarities between SARS-CoV-2 and its sister virus SARS-CoV [1], there are many differences that have been uncovered over the past three years [2]. For example, several antibodies derived from convalescent patients who developed a
successful immune response against the SARS-CoV virus were unable to demonstrate effective neutralization capacity against SARS-CoV-2 pseudovirus and prevent entry into target cells expressing the angiotensin converting enzyme 2 protein (ACE2) [3]. ACE2 represents the dominant entry receptor for both SARS-CoV and SARS-CoV-2 via engagement with the virion’s spike (S) protein [4]. However, it has been recently shown that due to the presence of various mutations in the receptor binding domain (RBD) domain of SARS-CoV-2, its ability to bind to ACE2 can be dramatically increased thus potentially increasing viral entry [5], escaping of antibody responses [6], and propagation of new variants through populations [7]. It has been also demonstrated that a proteolytic receptor called transmembrane protease serine 2 (TMPRSS2) also plays a significant role in priming the SARS-CoV-2 spike protein and facilitating membrane fusion [8, 9]. Recently, CD26 [10] and Neuropilin-1 [11] have also been propounded as proteins that facilitate viral entry. Another receptor called Basigin, also known as CD147, has been recently proposed to serve as an additional entry receptor for SARS-CoV-2 [12], although it is still debatable [13].

While the fundamental mechanism by which SARS-CoV-2 interacts with CD147 in humans is debated in the scientific community [13], there is a lot of potential rationales supporting the theory that CD147 could still play a role in the COVID-19 clinical course, even if it is not a functional viral entry receptor. For example, compared to ACE2 protein expression, CD147 is expressed in cardiomyocytes and endothelial cells, which may correlate with massive hemodynamic instability and cardiovascular abnormalities during SARS-CoV-2 infection [14, 15]. The high expression of CD147 protein, but not ACE2 protein, on erythrocytes and platelets, may also contribute to a "catch and clump" mechanism that increases the risk of thrombosis in various organ systems during SARS-CoV-2 infection [16]. Next, CD147 has been shown to serve as the potential entry receptor for a variety of other viral and non-viral pathogens as well, including rhinovirus [17], measles [18], meningitis [19], HIV-1 [19], and malaria [20]. This is potentially one reason that drugs such as hydroxychloroquine and azithromycin, which decrease the entry of Plasmodium falciparum [21–23], and Meplazumab (NCT04586153), a humanized anti-CD147 antibody, may have shown efficacy in small clinical studies during the early days of the pandemic [12, 24, 25]. However, some of these studies present several methodological weaknesses [26]. Indeed, some studies have shown that upon anti-CD147 antibody blocking, SARS-CoV-2 infection [27] and pseudotyped SARS-CoV-2 virus entry [28] are reduced, but other studies did not recapitulate this finding in other cell lines further indicating some biological nuance regarding its function [29]. However, because CD147 is implicated in many physiological [30] and immune processes [31, 32], a number of indirect mechanisms not related to viral entry may be able to explain these positive finding and provide support for further study in COVID-19 [33, 34]. Interestingly, one study observed that upon CD147 knockdown in the lung adenocarcinoma cell line CaLu3, ACE2 protein expression, but not ACE2 mRNA levels was markedly reduced [29]. Another study suggests that cell-cell transmission of SARS-CoV-2 virions may be mediated by other host receptors in addition to ACE2 further supporting the hypothesis of virion receptor promiscuity [35].

To this aim, we generated a humanized CD147 knock-in (hCD147KI) mouse model in the immunocompromised NOD-scid IL2Rgamma null (NSG) background, which lacks a functional immune
system (characterized by a lack of functional T, B, and Natural Killer cells). We performed several assays
to determine whether the expression of human CD147 could sufficiently and independently predispose
NSG mice to clinical manifestations of severe COVID-19 disease and found not only a moderate body
weight decline in mice carrying human CD147, but also infected cells containing SARS-CoV-2 RNA seven
days post-infection. Thus, the immunodeficient background of hCD147KI-NSG mice provides a useful
platform to dissect the role of specific immune cells during the SARS-CoV-2 clinical course development.
Further studies using this mouse model would be able to determine if CD147 mediates viral replication in
various other organs (such as the brain, gastrointestinal tract, reproductive organs, etc.) without the
confounding presence of a competent host immune system.

Materials And Methods

Genotyping for hCD147KI-NSG and hACE2KI-NSG mice

DNA from ear snips or toes was extracted using the HOTSHOT method for DNA preparation for screening
mice. Briefly, mice tissues were placed in 50 µL of alkaline lysis solution (25 mM NaOH, 0.2 mM EDTA)
and heated at 94°C for 30 minutes. 50 µL of neutralization solution (40 mM Tris-HCl, pH 5.0) was then
added to the extracted DNA. To screen mice for the hCD147 cDNA fragment, internal primers (hCD147A
and B) were used to generate a 223-base pair (bp) PCR fragment. To screen mice for the hACE2 cDNA
fragment, internal primers (hACE2A and B) were used to generate a 312-bp PCR fragment. To confirm
proper CRISPR-guided integration of the entire hCD147 and hACE2 construct within the mouse Bsg and
Ace2 alleles, respectively, DNA from toe or tail biopsies were extracted using Qiagen QIAmp DNA mini kit
(Qiagen, #51306) and anking primers were used to generate long PCR products encompassing the full
length of the cDNA constructs into the targeted alleles. A complete list of primer sequences used for
genotyping is provided in Table S1.

Immunohistochemistry (IHC) for CD147 on formalin-fixed
paraffin-embedded (FFPE) slides

Immunohistochemistry (IHC) was performed on FFPE tissue slides following a 45-minute antigen retrieval
step (pH 6.0). To stain human CD147 (hCD147) and SARS-CoV-2 Spike protein RBD, the Dako EnVision+
System- HRP Labelled Polymer kit (Agilent) was used according to manufacturer’s instructions against
slides incubated with primary mouse anti-human CD147 antibody (Biolegend, HIM6; 1:500) or primary
rabbit anti-RBD antibody (Sino Biological; 40592-T62; 1:800), respectively. To stain mouse CD147
(mCD147), polyclonal donkey anti-goat IgG secondary (Jackson ImmunoResearch; 705-035-003 [HRP];
1:500) was used against primary goat anti-mouse CD147 antibody (R&D Systems; BAF772; 1:100). Slides
were then incubated with 3,3’-Diaminobenzidine (DAB) for 4 minutes before washing and counterstained
with Gill No. 2 hematoxylin. Slides were then dehydrated and mounted for imaging.

Single-cell isolation of organ tissue and flow cytometry
staining
Organs and peripheral blood were obtained from euthanized adult hCD147K<sup>het</sup>-NSG and WT-NSG mice. Organs were then mechanically and chemically digested with Collagenase IV (Gibco, 17104019) for 10 minutes using the gentleMACS Octo with heater (Miltenyi) before triturating through a 70 µm cell strainer. The strained fraction was centrifuged at 400g for 5 minutes and then resuspended in ACK Lysis Buffer (Gibco, A1049201) for 5 minutes on ice. Phosphate-buffered saline (PBS) was added to quench the reaction and the cell suspension was centrifuged again. The supernatant was discarded, and the cell pellet was divided into various sample groups. Mouse cells were first preincubated with Fc Block according to manufacturer's recommendations before proceeding to antibody incubation. Mouse CD147 was stained using primary goat anti-mouse CD147 (R&D Systems, BAF772) and visualized using Cy5-conjugated polyclonal donkey anti-goat IgG secondary (Jackson ImmunoResearch; 705-175-147). Human CD147 was stained using primary FITC-conjugated mouse anti-human CD147 antibody (Invitrogen, MEM-M6/1) Antibodies were applied at a 1:100 dilution per sample for 30 minutes on ice, rinsed with PBS, and resuspended in PBS. Acquisition was performed on a BD Accuri™ C6 Plus system and downstream analysis was done using FlowJo (Tree star).

**Propagation of SARS-CoV-2 virus for in vivo infections**

To generate SARS-CoV-2 viral particles Vero E6 (ATCC# CRL-1586) cell monolayers were maintained in DMEM (Sigma-Aldrich; D5671) supplemented with 10% heat inactivated fetal bovine serum (Cytiva; sh30910.03). Flasks were inoculated with a dilution of 1:100 of SARS-CoV-2 USA-WA1/2020 isolate provided by the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) UTMB Arbovirus Reference Collection. After incubation at 37°C for 1 hour with gentle shaking every 15 minutes, inoculum was removed and replaced with fresh DMEM with 2% FBS. Stock SARS-CoV-2 virus was harvested at 72 hours post-infection and supernatants were collected, clarified, aliquotted, and stored at -80°C until use. The virus was titrated by the standard plaque-forming assay technique and TCID/50 using VERO E6 cells as described elsewhere [36].

**SARS-CoV-2 infection in NSG, hCD147-NSG, and hACE2-NSG mice**

12- to 20-week-old hCD147K<sup>het</sup>-NSG and WT littermates, and hACE2K<sup>homo</sup>-NSG mice were intranasally infected with $1 \times 10^5$ plaque-forming units (PFU) of SARS-CoV-2 and monitored daily for clinical deterioration and body weight drop for 2 or 7 days. Similarly, age-matched WT-NSG mice were given vehicle control (DMEM). At day 2 or day 7, mice were euthanized, and lung tissues were harvested. One lobe of the lung was disrupted in 0.75 mL Trizol in a Beadbeater (VWR, Radnor, PA) for RNA analysis by qRT-PCR. One lobe of the lung was homogenized in fresh DMEM with 2% FBS and used for flow cytometry analysis. The rest of the lung was preserved in 4% paraformaldehyde (PFA) for histology.

**qRT-PCR quantification for SARS-CoV-2 viral copies in infected mice lung tissue**
Real-time RT-PCR assays were carried out as described previously [37] in a 20-µL volume that contained 1x TaqPath 1-step RT-qPCR Master Mix (A28521, Thermo Fisher Scientific, Waltham, MA), 100 nM CoV-N forward primer, 500 nM CoV-N reverse primer, and 250 nM CoV-N molecular beacon probe. Each reaction was initiated with 2 µL RNA template. SARS-CoV-2 N gene transcript reference standard was purchased from ATCC (Manassas, VA, Cat. # VR3276SD) and used for quantitative analysis of N gene transcript levels in infected mouse lung tissues. The PCR assays were performed in 200-µL white polypropylene PCR tubes (USA Scientific, Ocala, FL) in a CFX96 Touch real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA). The thermal cycler was programmed to incubate the reaction mixtures for 10 minutes at 53°C to generate cDNA, followed by 2 minutes at 95°C to activate the DNA polymerase and then by 45 thermal cycles that consisted of DNA denaturation at 95°C for 15 seconds and primer annealing and elongation at 58°C for 60 seconds. Molecular beacon fluorescence intensity was monitored during the 58°C annealing and chain elongation stage of each thermal cycle. An additional qRT-PCR assay for the mouse GAPDH gene was designed for normalization purposes. For the GAPDH assay, the thermal cycler was programmed to incubate the reaction mixtures for 10 minutes at 53°C to generate cDNA, followed by 2 minutes at 95°C to activate the DNA polymerase and then by 45 thermal cycles that consisted of DNA denaturation at 95°C for 15 seconds and primer annealing and elongation at 60°C for 50 seconds. SybrGreen (Thermo Fisher; S7567) fluorescence intensity was monitored during the 60°C annealing and chain elongation stage of each thermal cycle. Primers were obtained from Integrated DNA Technologies (Coralville, IA) and the molecular beacon probe was obtained from LGC Biosearch Technologies (Petaluma, CA) and are listed in Table S1.

**Single molecule fluorescence in-situ hybridization (sm-FISH) probe design**

sm-FISH probe pools were generated to detect seven RNA+ segments of the SARS-CoV-2 genome (NCBI reference: NC_045512.2). Each probe pool used (~48 oligo probes per gene, each probe 20 nucleotides in length) is listed in Table S1. Probes were designed using Stellaris™ probe designer (Biosearch Technologies LGC, Petaluma, CA) and then synthesized and purchased from Biosearch Technologies (the probe sequences can be provided upon request). The 3’-end of each probe was modified with an amine group and coupled to Texas Red-X (Fisher Scientific). Coupled probes were ethanol precipitated and purified on an HPLC column to isolate oligonucleotides linked to the fluorophore, as described previously [38]. The seven sets of probes were diluted at 25 ng/ul, pooled each set with equal volumes together, and used at 25 ng per hybridization reaction (50 ul).

**sm-FISH staining in SARS-CoV-2 infected mouse lungs and image acquisition**

SARS-CoV-2 infected lung tissues were harvested at 2- or 7-days post-infection. Lungs were dissected and immediately fixed in 4% PFA, embedded in paraffin, and sectioned with a thickness of 0.7 µm. For sm-FISH staining, sections were deparaffinized, rehydrated, and subjected to heat-mediated antigen retrieval in 10 mM citrate buffer (0.173 g citric acid and 2.348 g sodium citrate in 100 mL RNAse free water, pH 6). Slides were then washed in hybridization wash buffer (10% formamide in 10% saline-sodium citrate
buffer) for 20 minutes. In the meantime, a humidified chamber for hybridization was prepared and pre-warmed at 37°C, 30 minutes before hybridization. After washing, each slide was incubated with 50 µL hybridization buffer (10% formamide, 10% dextran sulfate, 2 mM vanadyl-ribonucleoside complex, 0.02% RNase-free BSA, 0.001% *Escherichia coli* tRNA) with labeled viral RNA probes covering the whole tissue section in the humidifier chamber overnight at 37°C. After incubation, slides were washed twice in hybridization wash buffer for 10 minutes, received True Black (Biotium, Fremont, CA) for 1 minute and washed with hybridization wash buffer twice. Slides were then mounted in Mounting Medium with DAPI (Abcam, Waltham, MA) and imaged using Zeiss Axiovert 200M (20x, and 63x oil immersion objectives) controlled by MetaMorph image acquisition software (Molecular Devices, San Jose, CA). For 63x images, stacks of images of 16 layers with 0.2 µm interval at 100- to 2,000-millisecond exposure times were used in each fluorescence color channel including DAPI. Whole sections of lung tissue from hCD147KI-NSG (n = 3), hACE2KI-NSG (n = 4), and WT-NSG (n = 7) mice was scanned and representative infection sites with viral RNA signals were imaged.

**Immunohistochemistry (IHC) for SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) in mouse lung tissues**

FFPE slides of infected lung tissues were deparaffinized and subjected to antigen retrieval at 90°C for 40 minutes in 10 mM Citrate buffer. Slides were then incubated in blocking buffer [5% bovine serum albumin (BSA) in phosphate buffered saline (PBS)] at room temperature for 1 hour before being stained with primary rabbit anti-RBD antibody (diluted 1:400 in blocking buffer) overnight at 4°C. Then, slides were washed three times with PBS for 5 minutes before being stained with Alexa Fluor 488 conjugated goat anti-rabbit secondary antibody (Thermo Fisher, A-11034) at room temperature for 1 hour. Slides were washed three times and then mounted using Prolong Gold Antifade with DAPI (Invitrogen; P36935) and sealed before imaging.

**Quantification of total and mean fluorescence intensity (MFI) for SARS-CoV-2 Receptor Binding Domain (RBD) staining in lung tissues of infected mice**

The16-bit and 8-bit images were acquired of stained lung tissue from infected and control mice. 20 random fields were imaged per mouse. To obtain final quantification, image processing was done with Python and NumPy library [39]. Matrix manipulation in NumPy automated the evaluation process. The total and mean fluorescence intensity was calculated by dividing the total signal intensity over the area within a region of interest (ROI). The ROI for lung bronchiolar regions and alveoli were calculated by considering a threshold that separates the ROI from the background. To define the threshold, the 8-bit image version, which provides clear segregations between foreground and background, was used. To obtain the unmodified pixel values from the microscopical images, selected pixels from the 8-bit images were matched with their corresponding 16-bit images, and values for SARS-CoV-2 Spike protein RBD staining from 16-bit images were used for calculations and statistics.

**Quantification of various immune cell populations in the lungs of SARS-CoV-2 infected mice by flow cytometry**
Homogenized lungs suspensions from lungs of SARS-CoV-2 infected mice were rinsed and resuspended in PBS prior to staining with the following anti-mouse antibody cocktail for 30 minutes on ice: CD45-BV510 (BD; BDB563891), CD11b-FITC (BD; BDB557396), CD11C-Pe/Cy7 (BD; BDB558079), Ly6C-PerCP/Cy5.5 (BD; BDB560525), Ly6G-Alexa Fluor 700 (BD; BDB561236). Stained samples were then rinsed with PBS and resuspended in 4% PFA and allowed to fix for 72 hours in accordance with biosafety requirements before analyzing using a BD LSRFortessa™ X-20 Cell Analyzer. Flow data was quantified using FlowJo (Tree Star). Bioinformatic analysis was performed using GraphPad Prism 5.0 (GraphPad).

Results

Generation of human CD147 knock-in and human ACE2 knock-in mouse using CRISPR/Cas9

We developed a mouse model in which hCD147 was expressed in normal cells and tissue under the control of the endogenous Bsg/Cd147 gene promoter mimicking physiological expression (Fig. 1). Specifically, a human cDNA encoding CD147 was targeted to mouse CD147 exon 1 on chromosome 10. The resulting knock-in created a fusion protein with the first 22 amino acids of mouse CD147 signal peptide and amino acids 23–385 of human CD147 (NP_940991.1) that is expressed from the mouse CD147 promoter. Transcription termination was mediated by a bovine growth hormone polyadenylation signal sequence. Targeting was performed directly in NSG mouse embryos (JAX stock#: 005557) by co-injecting a targeting vector and Cas9 protein (IDT) complexed with a CRISPR sgRNA (IDT) recognizing and cutting the sequence 5’-GCCTGCGCGGCGGGTAAGAG-3’. Fourteen positive founders were determined to be correctly targeted by PCR genotyping and subsequent sequencing of the targeted alleles in their entirety. Three of the 14 were determined to be biallelic at the locus. The hCD147 frequencies and antigen density are close to human CD147 expression patterns in humans [40]. A representative genotype confirms the successful generation of the hCD147KI mouse [41], and the genotyping products were verified by DNA sequencing. Female mice are fertile and were able to transmit the KI allele to offspring. However, we observed lower fertility in hCD147KIhet-NSG males precluding the generation of a hCD147Kihomo-NSG mouse. Thus, hCD147KIhet-NSG mice were used for the purpose of evaluating SARS-CoV-2 sensitivity.

A similar strategy was used to generate a physiological expression model for the human angiotensin-converting enzyme 2 (hACE2) downstream of the mouse Ace2 gene on the X chromosome in the NSG background. Human ACE2 cDNA (Genbank seqID NM_011371415.1) was inserted in frame with mouse Ace2 using CRISPR-Cas9 in exon 1. The mouse Ace2 5’UTR and the first 15 amino acids of mouse Ace2 (MSSSSWLLLSTLVAVT) encoding the leader sequence were retained and the remainder of the sequence was replaced with the hACE2 cDNA sequence. Cas9 protein complexed with sgRNA containing the spacer sequence 5’-GAGCAGTAGTAACAGCAACA-3’ and plasmid targeting vector was microinjected into NSG zygotes. Founders were screened for integration of human ACE2 cDNA, then screened for proper targeting to the mouse locus by PCR using primers external from and internal to the targeting vector. PCR
fragments were purified and sequenced by the Sanger method to confirm the cloning junctions. Founders were bred to WT NSG mice and N1 progeny were confirmed to receive the targeted allele. Thus, the hCD147Ki-NSG and hACE2Ki-NSG mice were successfully generated using CRISPR/Cas9 technology.

**Verification of human CD147 protein expression in various tissues by immunohistochemistry**

After successful generation of hCD147Ki\(^{\text{het}}\)-NSG mice, we further verified human CD147 protein expression in these mice. Organs were harvested from adult hCD147Ki\(^{\text{het}}\)-NSG mice and WT-NSG littermates and stained for human CD147 protein by IHC (Fig. 2). We observed strong and specific hCD147 protein staining across all tissues assayed (lung, 2A; liver, 2B; intestine, 2C; heart, 2D; brain, 2E; spleen, 2F; kidney, 2G; testis, 2H) in knock-in mice compared to WT-NSG mice where no staining was visualized. Interestingly, we observed that red blood cells in the lung also expressed strong human CD147 staining indicating successful integration of the protein into erythrocyte precursors. The strongest staining was associated with bronchioles in the lungs relative to surrounding parenchyma, in condensing spermatids in the testes, and in mucosal villi in the intestines. Comparable tissue expression levels of human CD147 in hCD147Ki\(^{\text{het}}\)-NSG mice to that of mouse CD147 in WT-NSG mice was observed in sampled tissues as well (Figure S1). Hematoxylin & Eosin (H&E) stains in WT-NSG and hCD147Ki-NSG mice confirm proper architecture of each tissue (Fig. 2). Thus, we successfully generated the hCD147Ki-NSG mice with human CD147 protein expression in various tissues.

**Verification of co-expression of both hCD147 and mCD147 in various tissues and blood in hCD147Ki\(^{\text{het}}\)-NSG**

To confirm proper expression of both endogenous mouse CD147 and knock-in human CD147 in hCD147Ki\(^{\text{het}}\)-NSG mice, we first assessed antibody specificities against CD147 to preclude any cross-reactions between human and mouse tissues by testing them against the human liver cancer cell line HepG2 and the mouse liver cancer cell line BNL 1ME A.7R.1 (Figure S2). After observing no sign of cross-reaction between mouse and human cell lines, we further analyzed the expression of both proteins in various organs of hCD147Ki\(^{\text{het}}\)-NSG and WT-NSG mice by flow cytometry (Fig. 3). Successful co-expression of both proteins in hCD147Ki\(^{\text{het}}\)-NSG mice was observed in the peripheral blood mononuclear cells (Fig. 3A), lung (Fig. 3B), liver (Fig. 3C), and spleen (Fig. 3D) of knock-in mice but not in WT-NSG littermates. Together, we successfully generated the hCD147Ki\(^{\text{het}}\)-NSG mouse model, which can be used to test SARS-CoV-2 infection *in vivo*. Surface expression of the human CD147 protein was thus verified in PBMCs, Lung, Liver, and Spleen.

**Moderate sensitization of hCD147Ki-NSG mice and substantial sensitivity of hACE2Ki-NSG mice to SARS-CoV-2 infection, compared to WT-NSG littermates**

To evaluate whether human CD147 plays an active role in the pathogenesis of SARS-CoV-2 infection, we inoculated hCD147Ki\(^{\text{het}}\)-NSG mice with an infectious dose of SARS-CoV-2 (Fig. 4). We also
simultaneously infected hACE2\textsuperscript{homo}\textsubscript{NSG} mice to serve as both a positive indicator for successful viral infection, as well as to evaluate any clinical deterioration in the physiologically expressing hACE2\textsuperscript{homo}\textsubscript{NSG} mice, similar to that observed in the available K18-hACE2-B6 (The Jackson Laboratory, B6.Cg-Tg(K18-ACE2)2Prlmn/J, 034860) line. Expectedly, we observed ruffling of the fur and significant body weight drops (Fig. 4A) in hACE2\textsuperscript{homo}\textsubscript{NSG} mice at each timepoint compared to WT-NSG mice, which indicated that the method for establishing physiologically expressing mouse knock-in mice lines in the NSG background was successful. The body weights in infected hACE2\textsuperscript{homo}\textsubscript{NSG} mice did not return to initial weight levels by the end of the seven-day evaluation (Fig. 4A). Surprisingly, we observed a similar trend forming for hCD147\textsuperscript{het}\textsubscript{NSG} mice following SARS-CoV-2 infection that achieved significance at four days post-infection. Unexpectedly, we also observed a substantial recovery in hCD147\textsuperscript{het}\textsubscript{NSG} mice back to initial body weight levels by day seven. In a subsequent experiment, we observed slight trends in body weight drop in hCD147\textsuperscript{Ki-NSG} and significant body drops in hACE2\textsuperscript{Ki-NSG} mice and K18-hACE2\textsuperscript{Ki-B6} compared to WT-NSG mice (Figure S3).

To evaluate any differences in SARS-CoV-2 viral burden in the lungs of hCD147\textsuperscript{Ki-NSG} and hACE2\textsuperscript{Ki-NSG} mice, we also harvested the lungs of each mouse at day seven post-infection for immunohistochemical and molecular assessments. Consistent with previous literature [42], the hACE2\textsuperscript{Ki-NSG} mice developed a significant viral burden that persisted in the lungs for at least seven days post-infection. We observed a nearly 100,000-fold increase in the presence of SARS-CoV-2 nucleocapsid RNA in the lungs of hACE2\textsuperscript{Ki-NSG} mice compared to WT-NSG mice by qRT-PCR (Fig. 4B). Interestingly, we also found a nearly 65-fold increase in SARS-CoV-2 viral RNA in the lungs of hCD147\textsuperscript{Ki-NSG} mice, compared to WT-NSG mice, supporting the hypothesis that CD147 may play an accessory role in COVID-19 disease. In a subsequent experiment where mice were sacrificed two days post-infection, we observed slight fold increases in SARS-CoV-2 N-gene RNA levels (Figure S4) in SARS-CoV-2 infected hCD147\textsuperscript{Ki-NSG} mice compared to WT-NSG mice, confirming viral presence in hCD147\textsuperscript{Ki-NSG} mice 48 hours post-infection, albeit not to the degree of that in hACE2\textsuperscript{Ki-NSG} mice or the significantly infected K18-hACE2-B6 transgenic mice. To confirm our observations, we performed single molecule fluorescence in situ hybridization (sm-FISH) staining on fixed lung tissues from each NSG line. Consistent with our qRT-PCR findings, we observed signs of successful infection in the lungs of both hCD147\textsuperscript{Ki-NSG} and hACE2\textsuperscript{Ki-NSG} mice (1–2 infection sites and 2–5 infection sites per examined lung section, respectively) compared to WT-NSG lungs where no infection sites were detected from multiple surveyed areas (Fig. 4C). We were also able to confirm SARS-CoV-2 viral presence in hCD147\textsuperscript{Ki-NSG}, hACE2\textsuperscript{Ki-NSG}, and K18-hACE2-B6 mice in a subsequent experiment by sm-FISH microscopy (Figure S5) compared to infected WT-NSG mice 48 hours after infection demonstrating higher susceptibility of these knock-in and transgenic strains to viral infection during the early infection phase. Additionally, we also observed a significant increase in total CD45\textsuperscript{+} lymphocytes in the lungs of all infected knock-in and transgenic lines compared to the WT-NSG mouse line 48 hours after infection by flow cytometry and slight, but insignificant differences, in immune subpopulations (Figure S6) relative to the parent NSG line.
To further validate the presence of viral RNA, we evaluated the presence of the SARS-CoV-2 Spike protein RBD domain by IHC (Figure S7). We did observe RBD localization to the bronchiolar epithelial cells in all infected lines by conventional IHC and immunofluorescence, which is consistent with previous studies [43]. On assessing H&E sections, no significant inflammation-induced pathology in the lungs of any infected NSG mouse was observed. This is likely due to defective innate and humoral immune response systems in the NSG background. To quantify the total presence of SARS-CoV-2 in whole lung tissue histological specimens and on a per-cell basis, we calculated the mean and total fluorescence intensity of identically stained slides from infected hACE2KI-NSG, hCD147KI-NSG, and WT-NSG littermate controls (Figure S8). Briefly, slides were stained for the SARS-CoV-2 Spike protein RBD domain. A total of 20 random fields of lung tissue were acquired per mouse (Figure S8A). Then, image processing was performed using Python and NumPy to enumerate total signal intensity for pixels above a minimal background threshold (Figure S8B). Finally, the mean fluorescent intensity per field was determined by dividing the total intensity by the total number of pixels per field above minimum threshold. Consistent with our IHC data, hACE2Ki\textsubscript{homo}-NSG have substantially higher mean and total fluorescence intensity of SARS-CoV-2 Spike protein RBD fluorescence in lung tissues seven days post-infection compared to control WT-NSG mice (Figure S8C). In contrast, we observed no significant difference in total fluorescence between hCD147Ki\textsubscript{het}-NSG and their WT-NSG littermates and even noticed a small, but significant decrease in the MFI of RBD protein. In conclusion, we observed an increase in SARS-CoV-2 presence in both hCD147KI-NSG and hACE2KI-NSG mice at the RNA level, and an increase in hACE2KI-NSG, but not in hCD147KI-NSG mice at the RBD protein level.

**Discussion**

Whether CD147 serves as a functional receptor for SARS-CoV-2 infection is widely debated in the field of COVID-19 research. In this study, we generated two novel knock-in mouse models in the NSG background for: 1) hACE2, the putative receptor for SARS-CoV-2 entry (hACE2KI-NSG), and for 2) CD147, the potential accessory or co-receptor for coronavirus entry (hCD147KI-NSG). Next, we characterized the hCD147KI-NSG mice by flow cytometry and IHC and confirmed physiological distribution of the hCD147 protein across a variety of tissues in hCD147KI-NSG mice. Finally, we compared the ability of live SARS-CoV-2 virus to infect both knock-in models and observed significant amounts of viral RNA in lung tissues by smFISH and qRT-PCR.

Key to the development of successful and effective vaccines to SARS-CoV-2 infections and treatments for COVID-19 patients is the understanding SARS-CoV-2 infectivity and pathogenesis. The fundamental mechanism underlying SARS-CoV-2 entry remains poorly understood. Previous studies show that the spike proteins of SARS-CoV [4, 44] and SARS-CoV-2 [45–49] bind to hACE2, a well-recognized, functional receptor that mediates viral entry. A hACE2 transgenic (hACE2Tg) mouse model is being widely used [42, 43, 50, 51], which is clearly invaluable but with some limits (e.g., low expression of hACE2 in human lung, heart, and immune cells). Other models for studying SARS-CoV-2 infection in mice are currently being
optimized, including mouse-adapted virus derivations [52, 53], immunocompromised or obese mice that lack interferon receptors [53], or utilize cats, ferrets, and hamsters [54, 55].

However, while these models have recapitulated some aspects of the COVID-19 disease course, such as lung inflammation [56], cytokine storm [57], viral neuroinvasion [58], and impaired lung function [59], a majority of them cannot fully explain other aspects of COVID-19 disease, such as increased thrombosis risk, increased risk for severe COVID-19 disease in diabetic patients [60], associations between predisposing risk factors, such as stroke and immunosuppression, and clinical sequelae of COVID-19 [61–63].

Coronaviruses are known to have a high diversity of entry receptors, which includes the newly proposed human CD147 (hCD147) as a receptor for SARS-CoV-2. CD147 is a transmembrane glycoprotein with multiple functions in normal lung, immune cells, and diseased tissues [64]. Normal epithelial and fetal tissues have low expression of CD147, when measured by immunohistochemical analysis [65]. However, CD147 is significantly upregulated in aggressive and chronic disease states, such as in cancers [66, 67], atherosclerosis [68], diabetes [69], ischemic stroke [70], and chronic lung obstruction diseases [71]. Additionally, CD147 is strongly expressed on endothelial cells in the brain [72], gastrointestinal tract tissues [73], platelets [74], conjunctival tissues [75], kidney glomerular cells and podocytes [76], and cardiac pericytes [16, 77], where it could serve a more dominant role in SARS-CoV-2 infection and mediate COVID-19-related neurological disturbance, digestive tract vascular damage, increased thrombosis, conjunctivitis, acute kidney injury, and cardiovascular disruption, respectively. Intriguingly, recent studies show that CD147 plays a functional role in facilitating SARS-CoV and SARS-CoV-2 entry [78, 79], and antibodies against CD147 block the infection capabilities of SARS-CoV-2 [12]. A humanized anti-CD147 antibody (Meplazumab) efficiently improves the recovery of COVID-19 patients with pneumonia with a favorable safety profile [80]. However, the majority of studies related to CD147, and SARS-CoV-2 are focused on cell line-based in vitro assays and protein binding experiments and have yet-to-be verified in vivo [28, 81, 82]. Additionally, recent reports found no evidence of direct interaction between CD147 protein and the RBD domain of SARS-CoV-2 [13, 83]. Thus, it is imperative to verify a potential functional role of CD147 in a live mouse model.

The hCD147KI-NSG and hACE2KI-NSG mice developed in this study utilize the natural promoter for mouse Bsg and Ace2, respectively. The human keratin 18 promoter was used to overexpress hACE2 receptor in the epithelial cells of the most commonly used K18-hACE2-B6 model. Specifically, overexpression of human ACE2 was identified in airway epithelia and the epithelia lining the liver, kidney and gastrointestinal tract in K18-hACE2-B6 mice [43]. However, expression was not observed in alveolar epithelial cells. Additionally, as multiple integrations were determined to exist on mouse chromosome 2, hemizygous mice are estimated to have between 8 full copies (or 12–30 partial copies) (commissioned analysis by The Jackson Laboratory) which is essential to establishing such a robust model for SARS-CoV-2 infection. Unlike the COVID-19 disease process in humans which has a global mortality rate of between 1–10% [84], a majority of SARS-CoV-2 infected K18-hACE2-B6 mice succumb to the disease
process at an extremely rapid pace (as early as 6 days post-infection), making it difficult to study immunological responses [42].

CRISPR/Cas9 protein complexed with gRNA, along with the hCD147 or hACE2 plasmid constructs, were microinjected directly into NSG mouse zygotes, in order to generate a scarless knock-in of the human cDNA in frame within the first 22 amino acids of the mouse CD147 protein. Therefore, the human CD147 receptor and human ACE2 receptor are both expected to follow the same pattern of expression as the endogenous mouse receptor equivalents under normal conditions in hCD147KI-NSG and hACE2KI-NSG mice, respectively.

Our data supports the hypothesis that human CD147 plays an accessory role in SARS-CoV-2 infection. We confirmed strong expression of the human CD147 protein in the bronchiolar airway cells in hCD147KI-NSG mice compared to lung parenchymal cells. This protein distribution pattern may help explain why newer variants can replicate faster and more efficiently in the bronchus compared to lower airway regions [85]. Importantly, we observed increased viral presence measured by sm-FISH and qRT-PCR in the lungs of hCD147KI-NSG and hACE2KI-NSG mice, compared to WT-NSG littermates at both two days and 7 days after infection. While the overall degree of infection in hACE2KI-NSG mice was considerably more severe than that in hCD147KI-NSG mice, we observed a significant body weight drop, higher SARS-CoV-2 RNA level, and detected multiple SARS-CoV-2 infected cells in the lungs of both hCD147KI-NSG and hACE2KI-NSG mice for up to seven days post-infection, compared to WT-NSG mice. We also suspect that hCD147KI-NSG and hACE2KI-NSG mice may develop increased leukocytosis in the lungs shortly after SARS-CoV-2 infection. Unexpectedly, we did not observe a similar correlation in RBD levels in hCD147KI-NSG mice. This could be explained by three possible reasons: 1) sm-FISH and IHC may have different levels of sensitivity because sm-FISH detects the RNA expression level of SARS-CoV-2, which may represent an earlier window timepoint for detection, compared with IHC detection as it detects the protein. 2) this may be due to a divergence between viral RNA replication and viral protein production/clearance (or regulation) during the recovery phase seven-day post-infection, 3) CD147 may play a role in late phase cell-to-cell infection (Fig. 5), but not as a functional receptor (such as ACE2) to mediate viral entry, evidenced by the lack of a significant difference in viral load between infected WT-NSG and in hCD147KI-NSG mice measured by qRT-PCR at the early infection (Day 2).

Additionally, CD147 is an important immune-modulator [31] making it difficult to dissect mechanisms in infection models utilizing humanized immunocompetent mice. NSG mice, on the other hand, are immunocompromised and allow for unbiased evaluation of SARS-CoV-2 infectivity without immunological interference.

The limitations of the current study include small sample sizes and lack of exact molecular mechanisms. Future experiments will be able to compare the natural course of SARS-CoV-2 infection in immunocompromised hCD147KI-NSG and immunocompetent hCD147KI-B6 mice and will further elucidate the role of the human CD147 receptor during the SARS-CoV-2-induced immune response. While our results do not provide clarity on the mechanism by which this receptor enhances viral entry or
exacerbates viral replication and persistence, we confirm here that this model can set the stage for future inquiry and examination.

The hCD147KI model offers several strengths to the scientific community as it will better capture other nuances of the COVID-19 disease. (1) This model will allow researchers to study hemodynamic instability and increased thrombosis risk following COVID-19 infection as the hCD147 protein is expressed in circulating erythrocytes. (2) The NSG background will allow scientists to study how adoptive transfer can either dampen or exacerbate COVID-19-induced cytokine storm that is often seen in severe disease. Additionally, as the NSG background has been used to study diabetes [86], our model will allow further studies into the role of diabetes in COVID-19. (3) This model can be crossed with other mouse models to determine whether a combination of human CD147 and other viral entry-related receptors (e.g., ACE2, TMPRSS2) can exacerbate clinical disease as well via interactions between the two receptors to facilitate cell-to-cell transmission in different tissues or different time-points. If such a phenomenon is observed, the exact function of CD147 as an accessory receptor to the dominant viral entry receptor, ACE2, can be interrogated and properly confirmed in vivo (Fig. 5). (4) As the human CD147 protein is expressed at physiological levels in these mice, this model will better recapitulate true physiological conditions and expression patterns normally observed in mice and humans. Even if CD147 is later determined to play a relatively minor role compared to ACE2 in SARS-CoV-2 viral entry, this mouse model may prove to be invaluable for understanding how the virus globally impacts CD147-positive cells and tissues in the in vivo setting and how therapies may modulate COVID-19 disease via this receptor. (5) These models can be used to test the infectivity and pathogenesis of the emergence of variants of SARS-CoV-2, such as B.1.1.7 [alpha], B.1.351 [beta], B.1.617.2 [delta], P.1 (20J501Y.V3) [gamma], and B.1.621 [mu], and B.1.1.529 [omicron] to additional co-receptors, given recently reported studies showing mutation-driven extension of host range to common laboratory mice [87] and increased dependence on other accessory receptors other than ACE2 [85]. (6) As CD147 is expressed on many tissues and cell types outside of the respiratory system, if in fact this receptor is implicated in viral entry and dissemination, the hCD147KI-NSG model could help shed light onto the nature of chronic COVID-19 syndrome, also known as long COVID. (7) The hCD147KI-NSG background with hACE2 mouse model can be used to test novel immunotherapies (e.g., CAR-NK) to prevent and/or treat new mutants of SARS-CoV-2 in the future. In summary, the newly generated hCD147KI-NSG mouse model can be used as a platform where direct clinical implications for vaccine and therapeutic strategies can be evaluated in preparation for future global pandemics.

Conclusions

Currently available animal models available for the study of SARS-CoV-2 infection cannot explain many aspects of COVID-19 disease as it presents in humans such as increased thrombosis risk, increased risk of severe disease in patients with Diabetes or other comorbidities, and other clinical sequelae associated with SARS-CoV-2 infection. It has been suggested that due to its ability to serve as an entry receptor for other viruses including other coronaviruses, CD147, also known as Basigin, was recently proposed as a viral entry receptor for SARS-CoV-2. Here, we have successfully developed and validated expression of the
human CD147 receptor in immunocompromised NSG mice for the purposes of evaluating whether this protein can also serve as an additional functional or accessory receptor for SARS-CoV-2 viral entry and subsequent immune responses. Our data show that similar to the newly generated hACE2KI-NSG mice, hCD147KI-NSG mice are also more sensitive to SARS-CoV-2 infection compared to WT-NSG mice characterized by a moderate body weight decline post-infection correlated with persistent viral presence in the lungs for up to 7 days post-infection. However, the effect may not be induced by direct receptor binding via CD147. The hCD147KI-NSG mouse model generated in this study will help further elucidate the molecular mechanism(s) of CD147 in SARS-CoV-2 infection.

**Abbreviations**

Bp  
Base-pair  
BSA  
Bovine serum albumin  
COVID-19  
Coronavirus-Disease of 2019  
DAB  
3,3'-Diaminobenzidine  
FFPE  
Formalin-fixed paraffin embedded  
H&E  
Hematoxylin & Eosin  
hACE2  
Human angiotensin-converting enzyme 2  
hACE2Tg  
Human angiotensin-converting enzyme 2 transgenic  
hCD147  
Human CD147  
hCD147KI  
Human CD147 Knock-in  
IHC  
Immunohistochemistry  
K18-hACE2-B6  
B6.Cg-Tg(K18-ACE2)2Prlmn/J  
mCD147  
Mouse CD147  
MFI  
Mean fluorescence intensity  
NSG  
NOD-scid IL2Rgammnull
Declarations

Ethics approval and consent to participate: All animal experiments have been approved by the Rutgers Institutional Animal Care and Use Committee (IACUC, PROTO201800200). NSG mice from The Jackson Laboratory (Bar Harbor, ME) were used for all, in vivo, breeding experiments.

Consent for publication: Not applicable.

Availability of data and materials: The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by grants from HL125018 (D. Liu), AI124769 (D. Liu), AI129594 (D. Liu), AI130197 (D. Liu), CA267368 (D. Liu), CA227291 (S. Tyagi), and Rutgers-Health Advance Funding (NIH REACH program, D. Liu) from U01HL150852 (R. Panettieri, S. Libutti, and R. Pasqualini), and Rutgers University-New Jersey Medical School Startup funding for D. Liu Laboratory. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number T32AI125185. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Authors' contributions: DFL and SB conceived, designed the study, and interpreted the data. DFL and SB wrote the manuscript. PR and GY generated the hCD147KI-NSG mouse model. SB, QJ, and other authors (including AN, HT, YB, SM, ANN, ST, FC, PR, GY, DE, MLG, DA, RR, WG, and LS) performed the validation
experiments, in-vivo infection, analyzed the data, and contributed to the interpretation. All authors have read and approved the manuscript.

Acknowledgement:

We would like to thank the members of the D. Liu laboratory (Dr. Xueling Wang, Youssef Sabha, Minh Ma) for their helpful comments on the manuscript. We thank Dr. Padmini Salgame (PHRI) for BLS-3 animal experimental design recommendations. We would also like to thank Minh T. Doan from the Division of Neuropathology at University Hospital for her help with performing the IHC experiments.

Conflict of interest. All authors declare that they have no conflict of interest.

References

1. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671–80 e672.

2. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181(4):894–904 e899.

3. Anderson DE, Tan CW, Chia WN, Young BE, Linster M, Low JH, Tan YJ, Chen MI, Smith GJD, Leo YS, et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):900–2.

4. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.

5. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–4.

6. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe. 2021;29(1):44–57 e49.

7. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, et al: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 2020, 9.

8. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA. 2020;117(13):7001–3.

9. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80. e278.
10. Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57(7):779–83.
11. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, et al. Neurilpin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370(6518):856–60.
12. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, Wei D, Zhang Y, Sun XX, Gong L, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5(1):283.
13. Shilts J, Crozier TWM, Greenwood EJD, Lehner PJ, Wright GJ. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. Sci Rep. 2021;11(1):413.
14. Veer M, Kumar AM, Ivanova V. COVID-19 and the Cardiovascular System. Crit Care Nurs Q. 2020;43(4):381–9.
15. Rastogi A, Tewari P. Covid 19 and its cardiovascular effects. Ann Card Anaesth. 2020;23(4):401–8.
16. Behl T, Kaur I, Aleya L, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Bungau S. CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. Sci Total Environ. 2022;808:152072.
17. Stamatiou R, Boukas K, Paraskeva E, Molyvdas PA, Hatziefthimiou A. Azithromycin reduces the viability of human bronchial smooth muscle cells. J Antibiot (Tokyo). 2010;63(2):71–5.
18. Watanabe A, Yoneda M, Ikeda F, Terao-Muto Y, Sato H, Kai C. CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J Virol. 2010;84(9):4183–93.
19. Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. J Biochem. 2016;159(5):481–90.
20. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, Mboup S, Ndir O, Kwiatkowski DP, Duraisingh MT, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature. 2011;480(7378):534–7.
21. Yeo AE, Rieckmann KH. Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro. Int J Parasitol. 1995;25(4):531–2.
22. Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Patel K, Mohapatra MK, Lakhani J, Devi CU, Adak T, et al. A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India. Am J Trop Med Hyg. 2005;73(6):1108–11.
23. Loughlin EH, Rice JB, Wells HS, Rappaport I, Joseph AA. The treatment of Plasmodium falciparum malaria with a single dose antimalarial; a preliminary report of the use of hydroxychloroquine, 7-chloro-4-(N-ethyl-N-B-hydroxyethylamino)-1-methylbutylamino)-quinoline diphosphate. Antibiot Chemother (Northfield). 1952;2(4):171–4.
24. Ulrich H, Pillat MM. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep. 2020;16(3):434–40.
25. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.

26. Rosendaal FR: Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. Int J Antimicrob Agents 2020, 56(1):106063.

27. Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, Wu G, Chen R, Zhang Z, Wei D, et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduct Target Ther. 2021;6(1):347.

28. Xu C, Wang A, Geng K, Honnen W, Wang X, Bruinies N, Singh S, Ferrara F, D'Angelo S, Bradbury ARM, et al: Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms. Viruses 2021, 13(6).

29. Fenizia C, Galbiati S, Vanetti C, Vago R, Clerici M, Tacchetti C, Daniele T: SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2. Cells 2021, 10(6).

30. Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, D'Alessandro A, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, et al. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget. 2017;8(4):6742–62.

31. Zhu X, Song Z, Zhang S, Nanda A, Li G. CD147: a novel modulator of inflammatory and immune disorders. Curr Med Chem. 2014;21(19):2138–45.

32. Jin R, Liu S, Wang M, Zhong W, Li G. Inhibition of CD147 Attenuates Stroke-Associated Pneumonia Through Modulating Lung Immune Response in Mice. Front Neurol. 2019;10:853.

33. Sehirli AO, Sayiner S, Serakinci N. Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147). Mol Biol Rep. 2020;47(10):8229–33.

34. Mahdian S, Zarrabi M, Panahi Y, Dabbagh S. Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations. Inf Med Unlocked. 2021;23:100541.

35. Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A 2022, 119(1).

36. Jureka AS, Silvas JA, Basler CF. Propagation, Inactivation, and Safety Testing of SARS-CoV-2. Viruses 2020, 12(6).

37. Dikdan RJ, Marras SAE, Field AP, Brownlee A, Cironi A, Hill DA, Tyagi S. Multiplex PCR Assays for Identifying all Major SARS-CoV-2 Variants. J Mol Diagn 2022.

38. Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat Methods. 2008;5(10):877–9.

39. Harris CR, Millman KJ, van der Walt SJ, Gomers R, Virtanen P, Courmapeau D, Wieser E, Taylor J, Berg S, Smith NJ, et al. Array programming with NumPy. Nature. 2020;585(7825):357–62.
40. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K. High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006;119(8):1800–10.

41. Tseng H-c, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang J-. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11(1):4810. g et al.

42. Oladunni FS, Park JG, Pino PA, Gonzalez O, Akhter A, Allue-Guardia A, Olmo-Fontanez A, Gautam S, Garcia-Vilanova A, Ye C, et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020;11(1):6122.

43. McCray PB Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia HP, Halabi C, Sigmund CD, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–21.

44. Dimitrov DS. The secret life of ACE2 as a receptor for the SARS virus. Cell. 2003;115(6):652–3.

45. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020.

46. Lukassen S, Lorenz Chua R, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J 2020.

47. Qiu Y, Zhao YB, Wang Q, Li JY, Zhou ZJ, Liao CH, Ge XY. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. Microbes Infect 2020.

48. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020.

49. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.

50. Yang XH, Deng W, Tong Z, Liu YX, Zhang LF, Zhu H, Gao H, Huang L, Liu YL, Ma CM, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med. 2007;57(5):450–9.

51. Tseng CT, Huang C, Newman P, Wang N, Narayanan K, Watts DM, Makino S, Packard MM, Zaki SR, Chan TS, et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol. 2007;81(3):1162–73.

52. Leist SR, Dinnon KH 3rd, Schafer A, Tse LV, Okuda K, Hou YJ, West A, Edwards CE, Sanders W, Fritch EJ, et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020;183(4):1070–85 e1012.

53. Rathnasinghe R, Jangra S, Cupic A, Martinez-Romero C, Mulder LCF, Kehrer T, Yildiz S, Choi A, Mena I, De Vrieze J, et al: The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv 2021.

54. Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, Peiris JS, Lim W, Osterhaus AD. Virology: SARS virus infection of cats and ferrets. Nature. 2003;425(6961):915.
55. Roberts A, Vogel L, Guarner J, Hayes N, Murphy B, Zaki S, Subbarao K. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol. 2005;79(1):503–11.

56. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830–3.

57. Gu T, Zhao S, Jin G, Song M, Zhi Y, Zhao R, Ma F, Zheng Y, Wang K, Liu H, et al. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. Front Immunol. 2020;11:621441.

58. Kumari P, Rothan HA, Natekar JP, Stone S, Pathak H, Strate PG, Arora K, Brinton MA, Kumar M. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice. Viruses 2021, 13(1).

59. Dinnon KH 3rd, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL Jr, Hou YJ, Adams LE, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560–6.

60. Raony I, Saggioro de Figueiredo C. Retinal outcomes of COVID-19: Possible role of CD147 and cytokine storm in infected patients with diabetes mellitus. Diabetes Res Clin Pract. 2020;165:108280.

61. Singh V, Beer A, Kraus A, Mang F, Zhang X, Xue J, Hagemann N, Hermann DM, Gunzer M. Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs. Brain Behav Immun 2021.

62. Zhai P, Ding Y, Li Y. The impact of COVID-19 on ischemic stroke. Diagn Pathol. 2020;15(1):78.

63. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10.

64. Hahn JN, Kaushik DK, Yong VW. The role of EMMPRIN in T cell biology and immunological diseases. J Leukoc Biol. 2015;98(1):33–48.

65. Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, Zhang Y, Liao CG, Bian HJ, Jiang JL, et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology. 2009;54(6):677–87.

66. Xiong L, Edwards CK 3rd, Zhou L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci. 2014;15(10):17411–41.

67. Peng F, Li H, You Q, Li H, Wu D, Jiang C, Deng G, Li Y, Li Y, Wu Y. CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis. Biomed Res Int. 2017;2017:5019367.

68. Wang C, Jin R, Zhu X, Yan J, Li G. Function of CD147 in atherosclerosis and atherothrombosis. J Cardiovasc Transl Res. 2015;8(1):59–66.

69. Xie Y, Wang Y, Ding H, Guo M, Wang X, Dong Q, Cui M. Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target? J Neuroinflammation. 2019;16(1):72.

70. Patrizz A, Doran SJ, Chauhan A, Ahnstedt H, Roy-O’Reilly M, Lai YJ, Weston G, Tarabishy S, Patel AR, Verma R, et al. EMMPRIN/CD147 plays a detrimental role in clinical and experimental ischemic
stroke. Aging. 2020;12(6):5121–39.

71. Yu Q, Yang D, Chen X, Chen Q. CD147 increases mucus secretion induced by cigarette smoke in COPD. BMC Pulm Med. 2019;19(1):29.

72. Morgun AV, Salmin VV, Boytsova EB, Lopatina OL, Salmina AB. Molecular Mechanisms of Proteins - Targets for SARS-CoV-2 (Review). Sovrem Tekhnologii Med. 2021;12(6):98–108.

73. Bortolotti D, Simioni C, Neri LM, Rizzo R, Semprini CM, Occhionorelli S, Laface I, Sanz JM, Schiuma G, Rizzo S, et al. Relevance of VEGF and CD147 in different SARS-CoV-2 positive digestive tracts characterized by thrombotic damage. FASEB J. 2021;35(12):e21969.

74. Maugeri N, De Lorenzo R, Clementi N, Antonia Diotti R, Criscuolo E, Godino C, Tresoldi C, Angels For Covid-Bio BSGB, Bonini C, Clementi M, et al. Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. J Thromb Haemost. 2022;20(2):434–48.

75. Singh S, Garcia G Jr, Shah R, Kramerov AA, Wright RE 3rd, Spektor TM, Ljubimov AV, Arumugaswami V, Kumar A. SARS-CoV-2 and its beta variant of concern infect human conjunctival epithelial cells and induce differential antiviral innate immune response. Ocul Surf. 2022;23:184–94.

76. Kalejaiye TD, Bhattacharya R, Burt MA, Travieso T, Okafor AE, Mou X, Blasi M, Musah S: BSG/CD147 and ACE2 receptors facilitate SARS-CoV-2 infection of human iPS cell-derived kidney podocytes. bioRxiv 2021.

77. Avolio E, Carrabba M, Milligan R, Kavanagh Williamson M, Beltrami AP, Gupta K, Elvers KT, Gamez M, Foster RR, Gillespie K, et al. The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clin Sci (Lond). 2021;135(24):2667–89.

78. Chen Z, Mi L, Xu J, Yu J, Wang X, Jiang J, Xing J, Shang P, Qian A, Li Y, et al. Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus. J Infect Dis. 2005;191(5):755–60.

79. Ke Wang WC, Zhou Y-S, Lian J-Q, Zhang Z, Du P, Gong L, Zhang Y, Cui H-Y, Geng J-J, Wang B, Sun X-X, Wang C-F, Yang Xu, Lin P, Deng Y-Q, Wei D, Yang X-M, Zhu Y-M, Zhang K, Zheng Z-H, Jinf-Lin Miao, Ting Guo, Ying Shi, Zhang J, Fu L, Wang Q-Y, Huijie Bian, Ping Zhu, Zhi-Nan Chen: SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv 2020.

80. Huijie Bian Z-HZ, Wei D, Zhang Z, Kang W-Z, Hao C-Q, Dong K, Kang W, Xia J-L, Miao J-L, Xie R-H, Wang B, Sun X-X, Yang X-M, Lin P, Geng J-J, Wang K, Cui H-Y, Zhang K, Chen X-C, Tang H, Du H, Yao N, Liu S-S, Liu L-N, Zhang Z, Gao Z-W, Nan G, Wang Q-Y, Jian-Qi Lian, Zhi-Nan Chen, Ping Zhu: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv 2020, 2020.03.21.20040691.

81. Faghihi H. CD147 as an alternative binding site for the spike protein on the surface of SARS-CoV-2. Eur Rev Med Pharmacol Sci. 2020;24(23):11992–4.

82. Helal MA, Shouman S, Abdelwaly A, Elmehrath AO, Essawy M, Sayed SM, Saleh AH, El-Badri N. Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia. J Biomol Struct Dyn 2020:1–11.
83. Ragotte RJ, Pulido D, Donnellan FR, Hill ML, Gorini G, Davies H, Brun J, McHugh K, King LDW, Skinner K, et al: Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein. mSphere 2021, 6(4):e00647-21.

84. Sofi MS, Hamid A, Bhat SU. SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. Biosaf Health. 2020;2(4):217–25.

85. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, Kam TT, Gu H, Sit KY, Hsin MKY, et al: SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 2022.

86. Brehm MA, Bortell R, Diiorio P, Leif J, Laning J, Cuthbert A, Yang C, Herlihy M, Burzenski L, Gott B, et al. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice. Diabetes. 2010;59(9):2265–70.

87. Montagutelli X, Prot M, Levillayer L, Salazar EB, Jouvion G, Conquet L, Donati F, Albert M, Gambaro F, Behillil S, et al: The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice. bioRxiv 2021:2021.2003.2018.436013.

Figures

Figure 1

Schematic representation of genotyping primers used to confirm hCD147KI expression. A combination of 4 primers was used to screen mice (internal primers hCD147A and hCD147B) and confirm proper integration into the mouse CD147 allele (flanking primers BSGC and BSGD).
Figure 2

**H&E and IHC of human CD147 in hCD147K\textsuperscript{het}-NSG mice.** Human CD147 was stained (HIM6; 1:500) in the (A) lung, (B) liver, (C) intestine, (D) heart, (E) brain, (F) spleen, (G) kidney, (H) testis in WT-NSG (top) and hCD147K\textsuperscript{het}-NSG (bottom) mice. Images were taken using an Olympus Inverted Light Microscope. Scale bar represents 200 µm.

Figure 3

**Flow cytometric analysis reveals proper dual-expression of both mCD147 and hCD147 in PBMCs and various organs.** Representative contour plots of CD147 expression on WT-NSG (top) and hCD147K\textsuperscript{het}-NSG (bottom) cells from (A) PBMCs, (B) lung, (C) liver, and (D) spleen using antibodies targeting either mouse CD147 protein, human CD147 protein, or a combination of both antibodies (far right). Relative percentages are listed, and significant shifts highlighted in red. Gating was determined based on donkey anti-goat / mouse isotype IgG antibody background staining.

Figure 4

**Increased sensitivity of hCD147K\textsuperscript{I}-NSG and hACE2-NSG mice to SARS-CoV-2 viral infection compared to WT-NSG littermates.** (A) Average body weight loss as a percent of original body weight in WT-NSG, hCD147K\textsuperscript{I}-NSG, and hACE2K\textsuperscript{homo}-NSG mice following intranasal infection with the TCID50 dose of SARS-CoV-2 virus (1 x 10\textsuperscript{5} PFU in 25 µL per nostril). Error bars represent standard error measure (SEM). (B) Quantification of total SARS-CoV-2 viral copies in the lungs of infected mice at day 2 post-infection by qRT-PCR, as represented by total N-gene RNA copies per lung lobe (left) and by N-gene log-2 fold-change relative to WT-NSG mice (right). Mean values (red) are listed above each group. Each data point represents the average of two duplicate qRT-PCR assays from one mouse lung RNA preparation. (C) Representative sm-FISH images at 20X (first 3 columns) and 63X (4\textsuperscript{th} column, zoom on region of interest along with Differential Interference Contrast (DIC) overlay) magnifications showing SARS-CoV-2 RNA detection in lung sections from WT (top), hCD147K\textsuperscript{I} (middle), and hACE2K\textsuperscript{homo} (bottom) mice, seven days post-infection. Blue: DAPI; green: SARS-CoV-2 RNA. Scale bar represents 50 µm. N=5 in WT-NSG, n=3 in hCD147K\textsuperscript{I} and n=4 in hACE2K\textsuperscript{homo} mice. Statistical significance was determined using an unpaired
one-tailed t test. * indicates significance for comparisons between hACE2K^{homo}-NSG and WT-NSG mice and # indicates significance for comparisons between hCD147K^{het}-NSG and WT-NSG mice where number of symbols indicates significance strength (* or #, p<0.05; ** or ##, p<0.01).

Figure 5

Diagram of proposed working hypothesis of CD147 in SARS-CoV-2 Infection. (1) SARS-CoV-2 virions infect human cells via the canonical pathway where host Angiotensin-converting Enzyme 2 (ACE2) receptors bind to viral spike proteins (red) and facilitate viral entry and infection. (2) CD147 proteins, via binding to surface binding partners (e.g., E-selectin), facilitate cell-cell adhesion, membrane fusion, and intercellular transfer of SARS-CoV-2 virions. (3) Erythrocytes and platelets which strongly express CD147, bind SARS-CoV-2 virions, and increase thrombosis risk and other clinical manifestations of COVID-19.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- hCD147KISuppFigureLegend.docx
- hCD147KIsuppfigures.pptx